iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Kimia Biosciences gets permission for Bemopedoic acid bulk drug; Stock gains near 3%

18 May 2022 , 09:18 AM

Kimia Biosciences Ltd has been granted permission to manufacture and marketing of Bemopedoic acid Bulk Drug under New Drug and Clincial Trials Rules, 2019, under Drug & Cosmetics Acts, 1940 for manufacture and market of Bempedoic acid Bulk Drug.

As per the filing, the permission has been granted by Directorate General of Health Services Central Drugs Standard Control Organisation (New Drug Division) vide letter dated May 17, 2022.

At around 9:20 AM, Kimia Biosciences was trading at Rs39.85 per piece higher by 2.71% on the BSE.

Related Tags

  • Bemopedoic acid
  • Kimia Biosciences Ltd
  • Kimia Biosciences Ltd shares
  • Kimia Biosciences Ltd stocks
  • news
  • Pharma
  • recognition
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.